Literature DB >> 25828136

CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419.

Jure Samardzic1, Nada Bozina2, Bosko Skoric3, Lana Ganoci2, Mate Petricevic4, Miroslav Krpan3, Marijan Pasalic3, Davor Milicic3.   

Abstract

Entities:  

Keywords:  Acute coronary syndrome; CYP2C19; Clopidogrel; Pharmacogenetics; Platelet function testing; Tailoring therapy

Mesh：

Substances：

Year:  2015        PMID： 25828136     DOI： 10.1016/j.ijcard.2015.03.171

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  2 in total

1.  Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.

Authors:  Peng Dong; Xinchun Yang; Suyan Bian
Journal:  Med Sci Monit       Date:  2016-12-15

2.  Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.

Authors:  Samuel G Johnson; Paul B Shaw; Thomas Delate; Deanna L Kurz; Dylon Gregg; John C Darnell; Christina L Aquilante
Journal:  Pharm Pract (Granada)       Date:  2017-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.